Preclinical pipeline overview / Help fund a movie about AMR!

Dear All: Two things today.

First, Ursula Theuretzbacher, Miloje Savic, Christine Ardal, and Kevin Outterson have published in Nature Reviews Drug Discovery a brief but instructive snapshot of the global preclinical antibacterial pipeline. This report nicely complements the recent WHO analysis of the clinical pipeline that concluded that “the world is running out of antibiotics.”

You’ll want to read the paper yourself (it’s brief and open access), so I’ll just summarize by saying that Ursula and colleagues have analyzed applications from Year 1 of the CARB-X initiative, found a good diversity of approaches, and observed that this shows an encouraging alignment with the WHO priority pathogen list. This is encouraging, but these preclinical programs have still a long way to go, will require a lot of support en route, and are of course high risk. Discovery is hard, so let’s keep our fingers crossed!

Second, would you like to help fund a movie about antibiotic resistance? Bill Mudge, Jean Mudge, and Bob Milley are co-producers at Recombinant Films LLC. They have been steadily pulling together a internationally targeted documentary entitled Beating SuperBugs: Can We Win? for a generally educated but uninitiated audience. The documentary will focus on four of the CDC’s top superbug threats: tuberculosis; MRSA; C. difficile; and CRE. 

Using funds from a 2015 Kickstarter campaign, the team are now within about $100k of completing the film for release. If you’d like to help them get to done, you can make a tax-deductible contribution through their 501(c)3, non-profit fiscal sponsor, Catticus Corporation, Berkeley, CA. I think that non-technical material of this type is really valuable and I’m sure they’d appreciate any amount you might send.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Upcoming meetings of interest to the AMR community:

Share

EPA (part 5): Interagency Framework on AMR Risks of Antibacterial and Antifungal Pesticides

This is the fifth of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a second (28 Sep 2023) newsletter that expands on the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, and a 4th newsletter (27 Jan 2024) containing some additional resources. Dear All, Excitingly, the US EPA

HLM on AMR at UNGA: The end of the beginning

Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. Dear All (and with thanks to Damiano for co-authoring), Last week in NYC, the UN General Assembly (UNGA) and all its surrounding activities created a lot of energy (not to mention a giant traffic jam)! After a series of side meetings

Without action, AMR costs go from $66b to $159b/yr by 2050

Dear All, A new paper from Anthony McDonnell and a team led by the Center for Global Development extends estimates of the health-related impact of AMR (e.g., death) to a consideration of the economic ($) cost of AMR. To follow the plot, here are the links you will need: The new paper: “Forecasting the Fallout

UN TV: You can watch the AMR High-Level Meeting at UNGA

Dear All, The AMR HLM (High-Level Meeting) at the UN General Assembly starts at 10a ET today.  You can watch it here on UN TV: https://webtv.un.org/en/asset/k11/k11knc6w2t Addendum: It’s available for replay at that same link. See also the 1 Oct 2024 newsletter for a review of the HLM. All best wishes, –jr John H. Rex, MD

Scroll to Top